This page contains the I-MASK+ Prophylaxis
In October 2020, the FLCCC Alliance developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called i-Mask+. It’s centered around Ivermectin, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known.
It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical Discovery of a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19.
This page contains the I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 with guidance on the timing and doses of each component medication. The I-MASK+ Protocol complements our MATH+ Hospital Treatment Protocol for Covid-19 from March 2020, which is intended for hospitalized patients. Both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.FLCCC_Alliance-I-MASKplus-Protocol-v8-2021-01-12-ENGLISH
More info: I-mask+ by FLCCC